Detalhe da pesquisa
1.
The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.
Haematologica
; 102(9): 1617-1625, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28550183
2.
Genomewide association study on monoclonal gammopathy of unknown significance (MGUS).
Eur J Haematol
; 99(1): 70-79, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28375557
3.
A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance.
Eur J Haematol
; 99(1): 80-90, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28384387
4.
Multicentered patient-based evidence of the role of free light chain ratio normalization in multiple myeloma disease relapse.
Eur J Haematol
; 96(2): 119-27, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25816709
5.
Genomewide profiling of copy-number alteration in monoclonal gammopathy of undetermined significance.
Eur J Haematol
; 97(6): 568-575, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27157252
6.
Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies.
Blood Cancer J
; 13(1): 153, 2023 09 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37752128
7.
Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma.
Ann Hematol
; 90(12): 1441-7, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21380511
8.
Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy.
Biol Blood Marrow Transplant
; 16(4): 548-54, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-20005965
9.
Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies.
Clin Lymphoma Myeloma Leuk
; 18(6): e219-e240, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29793653
10.
Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients.
Curr Med Res Opin
; 34(5): 775-783, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29172760
11.
Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy.
PLoS One
; 10(4): e0123866, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25875484
12.
10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group.
Leuk Res
; 37(9): 1063-9, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23845888
13.
Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial.
Leuk Lymphoma
; 53(5): 920-7, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22023516